Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Impact of COVID-19 on short- and long-term outcomes in patients with diffuse large B-cell lymphoma: A real-world analysis.

Logesh Durairaj, Adithya Nagendran, Anushree Venkatesh Murthy et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19066

e19066 Background: Patients with diffuse large B-cell lymphoma (DLBCL) are highly vulnerable to infectious complications d...

Adjuvant nivolumab compared with platinum-based chemotherapy in bladder cancer: A real-world study.

Muhammad Yousaf, Yashan Thakkar, Jennifer Collins et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16563

e16563 Background: Both adjuvant platinum-based chemotherapy and nivolumab are used after radical cystectomy for high-risk...

An APP-led intake model to expedite diagnostic workup for patients with suspected lymphoma.

Erin Taylor, Jason Westin, Sairah Ahmed et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19111

e19111 Background: Lymphoma is a rare, heterogeneous malignancy that often presents with symptoms resembling benign, autoi...

Behavioral risk factor–attributable burden of gastrointestinal cancers: A global, site-specific quantification using GBD 2023.

Khaja Nayabrasool Syed, Harsha Sai Nelakuditi, Raghava Rao Alluri et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16363

e16363 Background: Behavioral risk factors drive a major fraction of gastrointestinal (GI) cancer deaths worldwide. We ana...

Deep learning–based PET/CT radiomics-clinical model for prognostic stratification and immunotherapy exploration in natural killer/T-cell lymphoma.

Tongyu Lin, Zegeng Chen, Huangming Hong et al. Jun 01, 2026 pp. 7072-7072 10.1200/jco.2026.44.16_suppl.7072

7072 Background: Natural killer/T-cell lymphoma (NKTCL) is a highly aggressive malignancy with substantial heterogeneity....

An EHR-embedded SmartForm (OncAssessment) paired with ePROs to enable real-time structured documentation of key oncologic data during routine cancer care: A pragmatic implementation study.

Aditi Puri Singh, Kate Barbour, Christiana Davis et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps1682

TPS1682 Background: Real-world evidence generation in oncology is often limited by inconsistent and unstructured documenta...

Trends in toxicity-associated hospitalizations and inpatient outcomes among gastrointestinal malignancies in the United States, 2016–2023.

Tajveer Sangha, Aishwarya Hanspal, Arman Manjikian et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23237

e23237 Background: Advances in systemic therapy for gastrointestinal (GI) malignancies have expanded rapidly, including im...

Online peer support for breast cancer survivors: A decentralized multicenter non-blinded parallel-group pilot randomized controlled trial (HOPE-BC study).

Yoshie Hasegawa, Ken Kurisu, Takashi Yamanaka et al. Jun 01, 2026 pp. 1668-1668 10.1200/jco.2026.44.16_suppl.1668

1668 Background: Peer support effectiveness for breast cancer survivors has reportedly varied, and no study has examined p...

Alliance A072301: A phase III trial of radiotherapy followed by adjuvant temozolomide in combination with vorasidenib vs placebo in <i>IDH</i> -mutated newly diagnosed grade 3 astrocytoma (VORTEX).

Ugonma Nnenna Chukwueke, Rifaquat Rahman, Susan Michelle Geyer et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2103

TPS2103 Background: Treatment for newly diagnosed IDH-mutant astrocytoma, WHO grade 3, is based on the results of the CATN...

Real-world outcomes of epcoritamab vs glofitamab in relapsed/refractory diffuse large B-cell lymphoma: A TriNetX retrospective study.

Juhi Ardeshna-Chovatiya, Amna Bint I Munir, Wei Ju Lin et al. Jun 01, 2026 pp. 7037-7037 10.1200/jco.2026.44.16_suppl.7037

7037 Background: Glofitamab and epcoritamab are CD20-directed bispecific antibodies that engage CD3-positive T cells and a...

Window of opportunity study of the Notch inhibitor AL101 in Notch1 activated adenoid cystic carcinoma (ACC): Biological effects and biomarker correlates.

Daniel McGrail, Felippe Lazar Neto, Yoshitsugu Mitani et al. Jun 01, 2026 pp. 6119-6119 10.1200/jco.2026.44.16_suppl.6119

6119 Background: ACC with NOTCH1 pathway activation (ACC-N1) is associated with aggressive clinical behavior and poor outc...

Individualized estimation of benefit from adjuvant docetaxel plus S-1 in stage III gastric cancer using deep learning–based counterfactual survival analysis of the START-2 trial.

Hiroki Sato, Wataru Ichikawa, Kazuhiro Yoshida et al. Jun 01, 2026 pp. 4095-4095 10.1200/jco.2026.44.16_suppl.4095

4095 Background: The START-2 trial demonstrated that docetaxel plus S-1 (DS) was superior to S-1 alone in terms of relapse...

Clinical outcomes among patients with metastatic non–small cell lung cancer (mNSCLC) who received immune checkpoint inhibitors (ICI) in first (1L) and second line (2L).

Terra Wonsettler, Adie Fridman, Aliza R. Karpes-Matusevich et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20578

e20578 Background: The use of ICIs, as monotherapy (mono) or with platinum-based chemotherapies, is the 1L standard of car...

AVATAR: Efficacy of personalized tumorogram-based therapy in breast cancer established from patient-derived organoids.

Luc Cabel, Rania El Botty, Romane Florent et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps1157

TPS1157 Background: Despite therapeutic advances in advanced breast cancer (ABC), predicting drug efficacy for individual...

The use of generative AI tools by cancer patients and caregivers: A cross-sectional survey of awareness, attitudes, and experiences.

Rashad Ismayilov, Arzu Oguz, Gizem Yılmaz Zenger et al. Jun 01, 2026 pp. 1612-1612 10.1200/jco.2026.44.16_suppl.1612

1612 Background: Generative artificial intelligence (AI) tools offer novel avenues for patient support, yet data on their...

Association between adverse childhood experiences (ACEs) and common cancers in the All of Us database.

Geraldine Kordai Mould, Marie Thearle, Rasheed Olaide Awodun et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24109

e24109 Background: ACEs are reportedly associated with increased cancer risk in adulthood, yet their relationship with spe...

Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma.

Alexandra Haugh, Mohamed A. Aboelatta, Kimberly Ward et al. Jun 01, 2026 pp. 9510-9510 10.1200/jco.2026.44.16_suppl.9510

9510 Background: Although acute toxicities associated with adoptive cellular therapy using lifileucel are well described a...

Efficacy and safety results of a prospective phase II study (IPUtrial) of inetetamab and pyrotinib in combination with utidelone for first- or second-line treatment of HER2-positive metastatic breast cancer.

Hui Cao, Tao Sun, Min Yan et al. Jun 01, 2026 pp. 1050-1050 10.1200/jco.2026.44.16_suppl.1050

1050 Background: Despite standard anti-HER2 regimens with chemotherapy, therapeutic challenges persist in HER2-positive me...

Safety signal dilution in cancer trials: Estimation of toxicities through term fragmentation.

Hila Nobel, Hadas Ditzian Kugler, Hadar Michaeli et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24134

e24134 Background: To harmonize global clinical reporting, standardized frameworks are used to classify the severity of ad...

Characterizing patient outcomes and tumor genetics in perinatal early-onset colorectal cancer patients.

Matthew Robert Moldenhauer, Irene Su, Nicole Elizabeth Lopez et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15738

e15738 Background: The overall incidence of colorectal cancer (CRC) in the United States is declining, however, the incide...

First-in-human study of in vivo CAR-T therapy GT801 in adults with relapsed or refractory CD19-positive B-cell hematologic malignancies.

Yarong Liu, Li Wang, Xianchao Ding et al. Jun 01, 2026 pp. 7079-7079 10.1200/jco.2026.44.16_suppl.7079

7079 Background: Despite high initial cure rates, patients with B-cell hematologic malignancies, including B-ALL and B-NHL...

Influence of cannabis use on relapse and remission rates in patients with acute lymphoblastic leukemia (ALL).

Eloho Olojakpoke, Deevyashali Parekh, Chidera Onwuzo et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18526

e18526 Background: There is a paucity of data regarding the impact of cannabis on relapse and remission rates, as well as...

Outcomes of malignant melanotic nerve sheath tumors (MMNST): A retrospective cohort study.

Cissimol Joseph, Reshma Vilson, Dejka M. Araujo et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23556

e23556 Background: MMNST is a rare and aggressive peripheral nerve sheath tumor characterized by melanocytic differentiati...

Systemic anticancer therapy near the end of life: A binational multicenter analysis in Argentina and Uruguay.

Melani Zlotogora, Milagros Wendebourg, Belen Insagaray et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24047

e24047 Background: Systemic anticancer therapy (SACT) near the end of life is considered a negative quality-of-care indica...

Clinical and genetic spectrum of 59 Birt-Hogg-Dubé patients in a single-institution cohort.

Maria Lampou, Lauren Bear, Michael N. Trinh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22663

e22663 Background: Birt-Hogg-Dubé (BHD) syndrome is a rare autosomal dominant disorder caused by germline pathogenic varia...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page